Safety monitoring of artemisinin combination therapy through a national pharmacovigilance system in an endemic malaria setting
The National Malaria Control Programme in Senegal, introduced since 2006, artemisinin-based combination therapy (ACT administration) for the treatment of uncomplicated malaria cases. In this framework, an anti-malarial pharmacovigilance plan was developed and implemented in all public health service...
Gespeichert in:
| Veröffentlicht in: | Malaria journal 2013-02, Vol.12 (1), p.54-54, Article 54 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 54 |
|---|---|
| container_issue | 1 |
| container_start_page | 54 |
| container_title | Malaria journal |
| container_volume | 12 |
| creator | Thiam, Sylla Ndiaye, Jean-Louis Diallo, Ibrahima Gatonga, Patrick Fall, Fatou Ba Diallo, Ndella E Faye, Babacar Diouf, Mamadou L Ndiop, Medoune Diouf, Mame B Gaye, Oumar Thior, Moussa |
| description | The National Malaria Control Programme in Senegal, introduced since 2006, artemisinin-based combination therapy (ACT administration) for the treatment of uncomplicated malaria cases. In this framework, an anti-malarial pharmacovigilance plan was developed and implemented in all public health services. This study investigated the occurrence of Adverse Drug Events (ADEs) after ACT.
The study was conducted between January 2007 and December 2009. It was based on spontaneous reports of ADEs in public health facilities. Data on patient demographic characteristics, dispensing facility, adverse signs and symptoms and causality were collected from a total of 123 patients.
The age range of these patients was six months to 93 years with a mean of 25.9 years. Of the reported symptoms, 46.7% were related to the abdomen and the digestive system. Symptoms related to the nervous system, skin and subcutaneous tissue, circulatory and respiratory systems and general symptoms and signs were 7%, 9.7%, 3.5% and 31.3%, respectively. Causality results linked 14.3% of symptoms to Falcimon® (Artesunate-Amodiaquine) with certainty. Effects were classified as mild and severe in 69.1% and 7.3% of cases respectively while 23.6% were serious. All patients with serious ADEs were hospitalized. One death was reported in a patient who had taken 24 pills at once.
These results confirm the need to develop and implement pharmacovigilance systems in malaria endemic countries in order to monitor the safety of anti-malarial treatments. |
| doi_str_mv | 10.1186/1475-2875-12-54 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3598537</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534653675</galeid><sourcerecordid>A534653675</sourcerecordid><originalsourceid>FETCH-LOGICAL-b580t-2f79b8daaeb1640eced3309e51f123b542acb6ca5137e33264c0ccd16f572bd13</originalsourceid><addsrcrecordid>eNp1kk1v1DAQhiMEoqVw5oYsceGS1h9xkr0gtRVQpEocgLM1cSa7rhJ7sZ1Ke-G3M9st2y4qsmRbntfPeN5xUbwV_FSItj4TVaNL2dIkZKmrZ8Xx_uT5o_1R8SqlG85F0zbyZXEklWorrurj4vd3GDBv2BS8yyE6v2RhYBAzTi457zyzYeqch-yCZ3mFEdYbWmOYlysGbBeAka1XECew4dYt3QjeIkubRBRGCPAMfU9EyyYYITpgCXOmZK-LFwOMCd_cryfFz8-fflxeldffvny9PL8uO93yXMqhWXRtD4CdqCuOFnul-AK1GIRUna4k2K62oIVqUClZV5Zb24t60I3seqFOio877nruJuwt-hxhNOvoJogbE8CZw4h3K7MMt0bpRatVQ4CLHaBz4T-AwwjZZrb-m63_RkijK4J8uH9FDL9mTNmQyRZH8gvDnIxQ1NOFpHQkff-P9CbMkYy-U1U1J3TzoFrCiMb5IVBuu4Wac62qWqu60aQ6fUJF464lwePg6Pzgwtnugo0hpYjDvk7BzfbfPVHZu8f-7vV_P5r6A5Vd1fM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1314604757</pqid></control><display><type>article</type><title>Safety monitoring of artemisinin combination therapy through a national pharmacovigilance system in an endemic malaria setting</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>Springer Nature - Complete Springer Journals</source><source>PubMed Central</source><creator>Thiam, Sylla ; Ndiaye, Jean-Louis ; Diallo, Ibrahima ; Gatonga, Patrick ; Fall, Fatou Ba ; Diallo, Ndella E ; Faye, Babacar ; Diouf, Mamadou L ; Ndiop, Medoune ; Diouf, Mame B ; Gaye, Oumar ; Thior, Moussa</creator><creatorcontrib>Thiam, Sylla ; Ndiaye, Jean-Louis ; Diallo, Ibrahima ; Gatonga, Patrick ; Fall, Fatou Ba ; Diallo, Ndella E ; Faye, Babacar ; Diouf, Mamadou L ; Ndiop, Medoune ; Diouf, Mame B ; Gaye, Oumar ; Thior, Moussa</creatorcontrib><description>The National Malaria Control Programme in Senegal, introduced since 2006, artemisinin-based combination therapy (ACT administration) for the treatment of uncomplicated malaria cases. In this framework, an anti-malarial pharmacovigilance plan was developed and implemented in all public health services. This study investigated the occurrence of Adverse Drug Events (ADEs) after ACT.
The study was conducted between January 2007 and December 2009. It was based on spontaneous reports of ADEs in public health facilities. Data on patient demographic characteristics, dispensing facility, adverse signs and symptoms and causality were collected from a total of 123 patients.
The age range of these patients was six months to 93 years with a mean of 25.9 years. Of the reported symptoms, 46.7% were related to the abdomen and the digestive system. Symptoms related to the nervous system, skin and subcutaneous tissue, circulatory and respiratory systems and general symptoms and signs were 7%, 9.7%, 3.5% and 31.3%, respectively. Causality results linked 14.3% of symptoms to Falcimon® (Artesunate-Amodiaquine) with certainty. Effects were classified as mild and severe in 69.1% and 7.3% of cases respectively while 23.6% were serious. All patients with serious ADEs were hospitalized. One death was reported in a patient who had taken 24 pills at once.
These results confirm the need to develop and implement pharmacovigilance systems in malaria endemic countries in order to monitor the safety of anti-malarial treatments.</description><identifier>ISSN: 1475-2875</identifier><identifier>EISSN: 1475-2875</identifier><identifier>DOI: 10.1186/1475-2875-12-54</identifier><identifier>PMID: 23384036</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antimalarials ; Antimalarials - adverse effects ; Antimalarials - therapeutic use ; Artemisinins - adverse effects ; Artemisinins - therapeutic use ; Case management ; Child ; Child, Preschool ; Complications and side effects ; Drug dosages ; Drug therapy ; Drug therapy, Combination ; Drug Therapy, Combination - adverse effects ; Drug Therapy, Combination - methods ; Drug-Related Side Effects and Adverse Reactions - epidemiology ; Endemic Diseases ; Female ; Health aspects ; Health facilities ; Health services ; Humans ; Infant ; Malaria ; Malaria - drug therapy ; Malaria - epidemiology ; Male ; Middle Aged ; Monitoring systems ; Patients ; Pharmacovigilance ; Population ; Public health ; Senegal - epidemiology ; Workers ; Young Adult</subject><ispartof>Malaria journal, 2013-02, Vol.12 (1), p.54-54, Article 54</ispartof><rights>COPYRIGHT 2013 BioMed Central Ltd.</rights><rights>2013 Thiam et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright ©2013 Thiam et al; licensee BioMed Central Ltd. 2013 Thiam et al; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b580t-2f79b8daaeb1640eced3309e51f123b542acb6ca5137e33264c0ccd16f572bd13</citedby><cites>FETCH-LOGICAL-b580t-2f79b8daaeb1640eced3309e51f123b542acb6ca5137e33264c0ccd16f572bd13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598537/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598537/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23384036$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thiam, Sylla</creatorcontrib><creatorcontrib>Ndiaye, Jean-Louis</creatorcontrib><creatorcontrib>Diallo, Ibrahima</creatorcontrib><creatorcontrib>Gatonga, Patrick</creatorcontrib><creatorcontrib>Fall, Fatou Ba</creatorcontrib><creatorcontrib>Diallo, Ndella E</creatorcontrib><creatorcontrib>Faye, Babacar</creatorcontrib><creatorcontrib>Diouf, Mamadou L</creatorcontrib><creatorcontrib>Ndiop, Medoune</creatorcontrib><creatorcontrib>Diouf, Mame B</creatorcontrib><creatorcontrib>Gaye, Oumar</creatorcontrib><creatorcontrib>Thior, Moussa</creatorcontrib><title>Safety monitoring of artemisinin combination therapy through a national pharmacovigilance system in an endemic malaria setting</title><title>Malaria journal</title><addtitle>Malar J</addtitle><description>The National Malaria Control Programme in Senegal, introduced since 2006, artemisinin-based combination therapy (ACT administration) for the treatment of uncomplicated malaria cases. In this framework, an anti-malarial pharmacovigilance plan was developed and implemented in all public health services. This study investigated the occurrence of Adverse Drug Events (ADEs) after ACT.
The study was conducted between January 2007 and December 2009. It was based on spontaneous reports of ADEs in public health facilities. Data on patient demographic characteristics, dispensing facility, adverse signs and symptoms and causality were collected from a total of 123 patients.
The age range of these patients was six months to 93 years with a mean of 25.9 years. Of the reported symptoms, 46.7% were related to the abdomen and the digestive system. Symptoms related to the nervous system, skin and subcutaneous tissue, circulatory and respiratory systems and general symptoms and signs were 7%, 9.7%, 3.5% and 31.3%, respectively. Causality results linked 14.3% of symptoms to Falcimon® (Artesunate-Amodiaquine) with certainty. Effects were classified as mild and severe in 69.1% and 7.3% of cases respectively while 23.6% were serious. All patients with serious ADEs were hospitalized. One death was reported in a patient who had taken 24 pills at once.
These results confirm the need to develop and implement pharmacovigilance systems in malaria endemic countries in order to monitor the safety of anti-malarial treatments.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antimalarials</subject><subject>Antimalarials - adverse effects</subject><subject>Antimalarials - therapeutic use</subject><subject>Artemisinins - adverse effects</subject><subject>Artemisinins - therapeutic use</subject><subject>Case management</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Complications and side effects</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Drug therapy, Combination</subject><subject>Drug Therapy, Combination - adverse effects</subject><subject>Drug Therapy, Combination - methods</subject><subject>Drug-Related Side Effects and Adverse Reactions - epidemiology</subject><subject>Endemic Diseases</subject><subject>Female</subject><subject>Health aspects</subject><subject>Health facilities</subject><subject>Health services</subject><subject>Humans</subject><subject>Infant</subject><subject>Malaria</subject><subject>Malaria - drug therapy</subject><subject>Malaria - epidemiology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monitoring systems</subject><subject>Patients</subject><subject>Pharmacovigilance</subject><subject>Population</subject><subject>Public health</subject><subject>Senegal - epidemiology</subject><subject>Workers</subject><subject>Young Adult</subject><issn>1475-2875</issn><issn>1475-2875</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp1kk1v1DAQhiMEoqVw5oYsceGS1h9xkr0gtRVQpEocgLM1cSa7rhJ7sZ1Ke-G3M9st2y4qsmRbntfPeN5xUbwV_FSItj4TVaNL2dIkZKmrZ8Xx_uT5o_1R8SqlG85F0zbyZXEklWorrurj4vd3GDBv2BS8yyE6v2RhYBAzTi457zyzYeqch-yCZ3mFEdYbWmOYlysGbBeAka1XECew4dYt3QjeIkubRBRGCPAMfU9EyyYYITpgCXOmZK-LFwOMCd_cryfFz8-fflxeldffvny9PL8uO93yXMqhWXRtD4CdqCuOFnul-AK1GIRUna4k2K62oIVqUClZV5Zb24t60I3seqFOio877nruJuwt-hxhNOvoJogbE8CZw4h3K7MMt0bpRatVQ4CLHaBz4T-AwwjZZrb-m63_RkijK4J8uH9FDL9mTNmQyRZH8gvDnIxQ1NOFpHQkff-P9CbMkYy-U1U1J3TzoFrCiMb5IVBuu4Wac62qWqu60aQ6fUJF464lwePg6Pzgwtnugo0hpYjDvk7BzfbfPVHZu8f-7vV_P5r6A5Vd1fM</recordid><startdate>20130205</startdate><enddate>20130205</enddate><creator>Thiam, Sylla</creator><creator>Ndiaye, Jean-Louis</creator><creator>Diallo, Ibrahima</creator><creator>Gatonga, Patrick</creator><creator>Fall, Fatou Ba</creator><creator>Diallo, Ndella E</creator><creator>Faye, Babacar</creator><creator>Diouf, Mamadou L</creator><creator>Ndiop, Medoune</creator><creator>Diouf, Mame B</creator><creator>Gaye, Oumar</creator><creator>Thior, Moussa</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7SS</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>F1W</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>H95</scope><scope>H97</scope><scope>K9.</scope><scope>L.G</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7T2</scope><scope>7U2</scope><scope>5PM</scope></search><sort><creationdate>20130205</creationdate><title>Safety monitoring of artemisinin combination therapy through a national pharmacovigilance system in an endemic malaria setting</title><author>Thiam, Sylla ; Ndiaye, Jean-Louis ; Diallo, Ibrahima ; Gatonga, Patrick ; Fall, Fatou Ba ; Diallo, Ndella E ; Faye, Babacar ; Diouf, Mamadou L ; Ndiop, Medoune ; Diouf, Mame B ; Gaye, Oumar ; Thior, Moussa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b580t-2f79b8daaeb1640eced3309e51f123b542acb6ca5137e33264c0ccd16f572bd13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antimalarials</topic><topic>Antimalarials - adverse effects</topic><topic>Antimalarials - therapeutic use</topic><topic>Artemisinins - adverse effects</topic><topic>Artemisinins - therapeutic use</topic><topic>Case management</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Complications and side effects</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Drug therapy, Combination</topic><topic>Drug Therapy, Combination - adverse effects</topic><topic>Drug Therapy, Combination - methods</topic><topic>Drug-Related Side Effects and Adverse Reactions - epidemiology</topic><topic>Endemic Diseases</topic><topic>Female</topic><topic>Health aspects</topic><topic>Health facilities</topic><topic>Health services</topic><topic>Humans</topic><topic>Infant</topic><topic>Malaria</topic><topic>Malaria - drug therapy</topic><topic>Malaria - epidemiology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monitoring systems</topic><topic>Patients</topic><topic>Pharmacovigilance</topic><topic>Population</topic><topic>Public health</topic><topic>Senegal - epidemiology</topic><topic>Workers</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thiam, Sylla</creatorcontrib><creatorcontrib>Ndiaye, Jean-Louis</creatorcontrib><creatorcontrib>Diallo, Ibrahima</creatorcontrib><creatorcontrib>Gatonga, Patrick</creatorcontrib><creatorcontrib>Fall, Fatou Ba</creatorcontrib><creatorcontrib>Diallo, Ndella E</creatorcontrib><creatorcontrib>Faye, Babacar</creatorcontrib><creatorcontrib>Diouf, Mamadou L</creatorcontrib><creatorcontrib>Ndiop, Medoune</creatorcontrib><creatorcontrib>Diouf, Mame B</creatorcontrib><creatorcontrib>Gaye, Oumar</creatorcontrib><creatorcontrib>Thior, Moussa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Malaria journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thiam, Sylla</au><au>Ndiaye, Jean-Louis</au><au>Diallo, Ibrahima</au><au>Gatonga, Patrick</au><au>Fall, Fatou Ba</au><au>Diallo, Ndella E</au><au>Faye, Babacar</au><au>Diouf, Mamadou L</au><au>Ndiop, Medoune</au><au>Diouf, Mame B</au><au>Gaye, Oumar</au><au>Thior, Moussa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety monitoring of artemisinin combination therapy through a national pharmacovigilance system in an endemic malaria setting</atitle><jtitle>Malaria journal</jtitle><addtitle>Malar J</addtitle><date>2013-02-05</date><risdate>2013</risdate><volume>12</volume><issue>1</issue><spage>54</spage><epage>54</epage><pages>54-54</pages><artnum>54</artnum><issn>1475-2875</issn><eissn>1475-2875</eissn><abstract>The National Malaria Control Programme in Senegal, introduced since 2006, artemisinin-based combination therapy (ACT administration) for the treatment of uncomplicated malaria cases. In this framework, an anti-malarial pharmacovigilance plan was developed and implemented in all public health services. This study investigated the occurrence of Adverse Drug Events (ADEs) after ACT.
The study was conducted between January 2007 and December 2009. It was based on spontaneous reports of ADEs in public health facilities. Data on patient demographic characteristics, dispensing facility, adverse signs and symptoms and causality were collected from a total of 123 patients.
The age range of these patients was six months to 93 years with a mean of 25.9 years. Of the reported symptoms, 46.7% were related to the abdomen and the digestive system. Symptoms related to the nervous system, skin and subcutaneous tissue, circulatory and respiratory systems and general symptoms and signs were 7%, 9.7%, 3.5% and 31.3%, respectively. Causality results linked 14.3% of symptoms to Falcimon® (Artesunate-Amodiaquine) with certainty. Effects were classified as mild and severe in 69.1% and 7.3% of cases respectively while 23.6% were serious. All patients with serious ADEs were hospitalized. One death was reported in a patient who had taken 24 pills at once.
These results confirm the need to develop and implement pharmacovigilance systems in malaria endemic countries in order to monitor the safety of anti-malarial treatments.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>23384036</pmid><doi>10.1186/1475-2875-12-54</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1475-2875 |
| ispartof | Malaria journal, 2013-02, Vol.12 (1), p.54-54, Article 54 |
| issn | 1475-2875 1475-2875 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3598537 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; Springer Nature OA Free Journals; Springer Nature - Complete Springer Journals; PubMed Central |
| subjects | Adolescent Adult Aged Aged, 80 and over Antimalarials Antimalarials - adverse effects Antimalarials - therapeutic use Artemisinins - adverse effects Artemisinins - therapeutic use Case management Child Child, Preschool Complications and side effects Drug dosages Drug therapy Drug therapy, Combination Drug Therapy, Combination - adverse effects Drug Therapy, Combination - methods Drug-Related Side Effects and Adverse Reactions - epidemiology Endemic Diseases Female Health aspects Health facilities Health services Humans Infant Malaria Malaria - drug therapy Malaria - epidemiology Male Middle Aged Monitoring systems Patients Pharmacovigilance Population Public health Senegal - epidemiology Workers Young Adult |
| title | Safety monitoring of artemisinin combination therapy through a national pharmacovigilance system in an endemic malaria setting |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T21%3A57%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20monitoring%20of%20artemisinin%20combination%20therapy%20through%20a%20national%20pharmacovigilance%20system%20in%20an%20endemic%20malaria%20setting&rft.jtitle=Malaria%20journal&rft.au=Thiam,%20Sylla&rft.date=2013-02-05&rft.volume=12&rft.issue=1&rft.spage=54&rft.epage=54&rft.pages=54-54&rft.artnum=54&rft.issn=1475-2875&rft.eissn=1475-2875&rft_id=info:doi/10.1186/1475-2875-12-54&rft_dat=%3Cgale_pubme%3EA534653675%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1314604757&rft_id=info:pmid/23384036&rft_galeid=A534653675&rfr_iscdi=true |